Traws Pharma Inc (TRAW)

Traws Pharma Inc (TRAW) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $5.7M; returns 1 day -6.6%, 1 week -7.3%, 1 year -87.0%.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral antiviral therapies to combat respiratory viral threats. Their pipeline includes Ratutrelvir, a ritonavir-free Mpro/3CL protease inhibitor for COVID-19, and Tivoxavir marboxil (TXM), a single-dose CAP-dependent endonuclease inhibitor for seasonal and avian influenza.

Groups TRAW belongs to

• Biotechnology
• Clinical Stage Biopharma
• Antivirals
• Healthcare
• Clinical Stage
• Infectious Diseases
• COVID-19
• Pharmaceuticals
• Life Sciences
• Drug Discovery

TRAW financial model: income statement, cash flow and balance sheet